IRONWOOD PHARMA INC CLASS A (IRWD)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for IRWD
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| IRWD | Venture Partner at Catalys Pacific Fund, LP | 68 | ["Venture partner at Catalys Pacific Fund, LP since March 2021","Former president and chief executive officer of Aravive, Inc. from 2015 to 2020","Executive chairman of Versartis, Inc. from 2013 to 2015","Executive partner at Sofinnova Ventures from 2008 to 2015","President and chief executive officer of NextWave Pharmaceuticals, Inc. from 2010 to 2012","Interim president and chief executive officer of Relypsa from 2005 to 2007","Vice president of commercial operations at Telik","Oncology business unit head of ALZA Pharmaceuticals","Over 35 years of experience in the pharmaceutical, biotechnology and drug delivery arenas","Participated in or led over 16 product launches","Holds a B.S. in Business Administration from the University of Arizona","Deep expertise in the pharmaceutical industry and recognized public company CEO and senior executive"] | ["Audit Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Venture Partner at Catalys Pacific Fund, LP Age: 68 Director since 2020 Board Committees Audit Committee Mr. Shepard has served as a venture partner at Catalys Pacific Fund, LP, a venture group focused on licensing drug programs and creating new companies in the U.S. and Japan, since March 2021. Mr. Shepard previously was president and chief executive officer of Aravive, Inc. (formerly Versartis, Inc.), a clinical-stage oncology company, from 2015 to 2020, when he retired. From 2013 to 2015, Mr. Shepard was executive chairman of Versartis, Inc. From 2008 until 2015, Mr. Shepard was an executive partner at Sofinnova Ventures, a venture capital firm focused on the healthcare industry. From 2010 to 2012, Mr. Shepard served as president and chief executive officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pediatric pharmaceutical company. From 2005 to 2007, Mr. Shepard served as interim president and chief executive officer of Relypsa (Ilypsa, Inc. s spin-out company, which was acquired by Galencia), a pharmaceutical company. Mr. Shepard was also vice president of commercial operations at Telik and oncology business unit head of ALZA Pharmaceuticals (acquired by J&J). Mr. Shepard has over 35 years of experience in the pharmaceutical, biotechnology and drug delivery arenas. Mr. Shepard has participated in or led over 16 product launches by preparing markets and establishing sales and marketing operations. Mr. Shepard also currently serves on the board of directors of the following public companies: Inovio Pharmaceuticals, Inc. (Nasdaq: INO) and Esperion Therapeutics, Inc. (Nasdaq: ESPR). In addition, Mr. Shepard serves on the board of directors of Aculys Pharma, LLC and Cessation Therapeutics, Inc., each of which is a privately held company. Mr. Shepard also serves on the board of directors of the Christopher & Dana Reeve Foundation. Mr. Shepard holds a B.S. in Business Administration from the University of Arizona. Mr. Shepard brings deep expertise to our board of directors, as a recognized leader within the pharmaceutical industry, with over three decades of expertise as an accomplished public company CEO and senior executive.